Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide controlled release - Calliditas Therapeutics

Next Previous
Drug Profile

Budesonide controlled release - Calliditas Therapeutics

Alternative Names: Kinpeygo; Nefecon; NEFEGAN; PL-56; TARPEYO; VR-205

Latest Information Update: 15 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Uppsala University
  • Developer Calliditas Therapeutics; Everest Medicines; Viatris Inc
  • Class Alcohols; Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Corticosteroids; Dioxoles; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy; Primary biliary cirrhosis; Autoimmune hepatitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed IgA nephropathy

Most Recent Events

  • 07 May 2025 Registered for IgA nephropathy in South Korea (PO), before May 2025
  • 07 May 2025 Registered for IgA nephropathy in Taiwan (PO), before May 2025
  • 07 May 2025 Everest Medicines plans to launch Nefecon® for Primary IgA nephropathy in Taiwan and South Korea later in 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top